Thyroid Cancers

A 73-Year-Old Woman With Differentiated Thyroid Cancer

September 25, 2020

Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.

Early Data Presented for Lenvatinib and Pembrolizumab in Thyroid Cancer

September 23, 2020

Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.

Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid Cancer

September 21, 2020

Larotrectinib as treatment of patients with TRK fusion-positive thyroid cancer had rapid and durable disease control, with the highest response rates observed in the differentiated thyroid cancer population.

A 71-Year-Old Woman with NTRK Gene Fusion Thyroid Cancer

September 21, 2020

A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.

Larotrectinib Elicits Rapid, Durable Responses in TRK Fusion-Positive Solid Tumors

September 20, 2020

Larotrectinib demonstrated rapid and durable as treatment of patients with TRK fusion-positive solid tumors, as well as a favorable long-term toxicity profile, according to an expanded pooled analysis from 3 clinical trials.

Ongoing ARROW Trial Data Support Pralsetinib as a Potential Treatment Option in RET-Mutant MTC

September 20, 2020

Patients with medullary thyroid cancer harboring abberations in RET who were treated with pralsetinib across therapy lines exhibited potent and durable clinical activity, according to results presented at the ESMO Virtual Congress 2020 from the phase 1/2 ARROW clinical trial.

Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid Cancer

September 19, 2020

Christine Dierks, MD, discusses the results from the prospective phase 2 ATLEP study of lenvatinib in combination with pembrolizumab as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.

FDA Grants Orphan Drug to Bispecific Antibody as Treatment of Thymic Epithelial Tumors

September 08, 2020

The FDA granted an Orphan Drug designation to KNO46 for the treatment of thymic epithelial tumors.

FDA Grants Priority Review to Pralsetinib for RET+ Thyroid Cancers

September 05, 2020

The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusion–positive thyroid cancer.

Fusion Genes Associated With More Aggressive Papillary Thyroid Cancer in Pediatric Patients

September 03, 2020

The most common genetic cause of alterations in pediatric patients with papillary thyroid cancer were fusion genes, which were associated with more aggressive disease.